Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Currently, we are focused on the hepatitis B virus capsid, the cytoplasmic dynein motor domain, and the role of carbohydrates and glycoconjugates in immunity and disease. "Assembly properties of ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Positive Phase 1b interim data released for ABI-4334, a next-generation highly potent capsid assembly modulator candidate for chronic HBV (cHBV) infection ABI-4334 was well-tolerated, with an ...